Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2017 06:52 ET | Source: Zogenix, Inc.

Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock

EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
September 29, 2017 07:00 ET | Source: Zogenix, Inc.

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
August 08, 2017 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan ...
August 01, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8

EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
June 22, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome

EMERYVILLE, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
May 31, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Present at the Jefferies 2017 Global Healthcare Conference

EMERYVILLE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
May 22, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
May 04, 2017 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results

Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome; Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of...
April 27, 2017 08:01 ET | Source: Zogenix, Inc.

Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome

EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
April 27, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4

EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right